MX387753B - Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. - Google Patents

Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.

Info

Publication number
MX387753B
MX387753B MX2016009428A MX2016009428A MX387753B MX 387753 B MX387753 B MX 387753B MX 2016009428 A MX2016009428 A MX 2016009428A MX 2016009428 A MX2016009428 A MX 2016009428A MX 387753 B MX387753 B MX 387753B
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
binding proteins
hereditary angioedema
treat hereditary
treat
Prior art date
Application number
MX2016009428A
Other languages
English (en)
Spanish (es)
Other versions
MX2016009428A (es
Inventor
Burt Adelman
Christopher Tenhoor
Daniel J Sexton
Jon A Kenniston
Joseph Biedenkapp
Ryan Faucette
Ryan Iarrobino
Yung Chyung
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2016009428A publication Critical patent/MX2016009428A/es
Publication of MX387753B publication Critical patent/MX387753B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2016009428A 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. MX387753B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (2)

Publication Number Publication Date
MX2016009428A MX2016009428A (es) 2017-04-13
MX387753B true MX387753B (es) 2025-03-18

Family

ID=53681890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009428A MX387753B (es) 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Country Status (18)

Country Link
US (3) US11084884B2 (2)
EP (3) EP3848057B1 (2)
JP (4) JP6845012B2 (2)
KR (4) KR102424183B1 (2)
CN (2) CN116585468A (2)
AU (3) AU2015209481C1 (2)
BR (1) BR112016016916B1 (2)
CA (1) CA2937329C (2)
DK (1) DK3096798T3 (2)
EA (1) EA038532B1 (2)
ES (1) ES2856076T3 (2)
IL (3) IL246864B (2)
MX (2) MX387753B (2)
NZ (2) NZ761006A (2)
PL (2) PL3096798T3 (2)
PT (1) PT3096798T (2)
WO (1) WO2015112578A1 (2)
ZA (2) ZA201605342B (2)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
EP4354146B1 (en) * 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
MX2020003888A (es) * 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
AU2020237259A1 (en) * 2019-03-14 2021-10-14 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20220315929A1 (en) * 2019-05-24 2022-10-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230174674A1 (en) * 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
IL321154A (en) * 2022-12-13 2025-07-01 Astria Therapeutics Inc Anti-plasma kallikrein antibody dosing regimens for the treatment of plasma kallikrein-related disorders

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7803553B2 (en) 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
US20070253949A1 (en) 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
EP2182978A4 (en) * 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR102607829B1 (ko) 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11340237B2 (en) * 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP3678553B1 (en) 2017-09-05 2024-05-22 Sanolla Ltd Diagnosis of pathologies using infrasonic signatures
CN113056304A (zh) 2018-08-30 2021-06-29 戴埃克斯有限公司 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
AU2020237259A1 (en) 2019-03-14 2021-10-14 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Also Published As

Publication number Publication date
KR20220107077A (ko) 2022-08-01
PL3848057T3 (pl) 2026-04-20
JP2024170495A (ja) 2024-12-10
JP6845012B2 (ja) 2021-03-17
US20210087293A1 (en) 2021-03-25
IL278062A (en) 2020-11-30
JP7164502B2 (ja) 2022-11-01
IL246864B (en) 2018-12-31
ZA202004653B (en) 2022-01-26
ES2856076T3 (es) 2021-09-27
IL278062B (en) 2022-06-01
KR20160122169A (ko) 2016-10-21
BR112016016916B1 (pt) 2023-12-19
US11084884B2 (en) 2021-08-10
CN106132442A (zh) 2016-11-16
KR20240033156A (ko) 2024-03-12
KR102903403B1 (ko) 2025-12-24
EP3096798A4 (en) 2017-08-23
PT3096798T (pt) 2021-02-25
CA2937329C (en) 2022-05-31
EP3848057B1 (en) 2025-12-10
CN116585468A (zh) 2023-08-15
JP2020002171A (ja) 2020-01-09
AU2020244370B2 (en) 2024-03-07
BR112016016916A8 (pt) 2018-05-02
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
MX2021013665A (es) 2021-12-10
AU2015209481A1 (en) 2016-08-25
WO2015112578A1 (en) 2015-07-30
ZA201605342B (en) 2020-11-25
JP2017503820A (ja) 2017-02-02
IL263669A (en) 2019-01-31
MX2016009428A (es) 2017-04-13
KR102424183B1 (ko) 2022-07-26
AU2015209481B2 (en) 2020-07-30
BR112016016916A2 (pt) 2018-01-23
EA038532B1 (ru) 2021-09-10
JP2023015087A (ja) 2023-01-31
PL3096798T3 (pl) 2021-07-26
CN106132442B (zh) 2023-07-14
EP3096798B1 (en) 2020-11-25
US20260035482A1 (en) 2026-02-05
CA2937329A1 (en) 2015-07-30
EA201691470A1 (ru) 2016-12-30
US20170002094A1 (en) 2017-01-05
EP3848057A1 (en) 2021-07-14
DK3096798T3 (da) 2021-03-01
IL263669B (en) 2020-10-29
AU2015209481C1 (en) 2020-10-29
EP3096798A1 (en) 2016-11-30
KR20240049627A (ko) 2024-04-16
AU2020244370A1 (en) 2020-10-29
EP4722720A2 (en) 2026-04-08
NZ761006A (en) 2023-04-28
AU2024203436A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MX387753B (es) Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
ZA201803661B (en) Compositions and methods for decreasing tau expression
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL251759B (en) Compositions and methods for treating insomnia
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DK2914630T3 (da) Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
MX2015003701A (es) Composiciones para tratamiento.
IL272246A (en) Compositions and methods for treating galactosemia
IL257764B (en) Methods for treatment of diseases
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
MX2018012230A (es) Métodos para tratar enfermedades oculares.
EA201791538A1 (ru) Способ предотвращения или лечения потери слуха
BR112017008097A2 (pt) método para tratar condições oculares
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
HUE052098T2 (hu) Prohemosztatikus fehérjék vérzés kezelésére
IL252707A0 (en) Compositions and methods for treating diseases and conditions
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
BR112017026193A2 (pt) agentes de clarificação para bioprocessamento de adsorventes e métodos de produção e uso dos mesmos
IL249483B (en) Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents